DOCSLIB.ORG

STUDIES on DIHYDROFOLIC REDUCTASE, HI. the ACTIVATION of DIHYDROFOLIC REDUCTASE from CHICKEN LIVER by Iodlne* by BERNARD T

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
STUDIES on DIHYDROFOLIC REDUCTASE, HI. the ACTIVATION of DIHYDROFOLIC REDUCTASE from CHICKEN LIVER by Iodlne* by BERNARD T STUDIES ON DIHYDROFOLIC REDUCTASE, HI. THE ACTIVATION OF DIHYDROFOLIC REDUCTASE FROM CHICKEN LIVER BY IODlNE* BY BERNARD T. KAUFMAN NATIONAL INSTITUTE OF ARTHRITIS AND METABOLIC DISEASES, NATIONAL INSTITUTES OF HEALTH Communicated by Max Tishler, June 23, 1966 Chicken liver dihydrofolic reductase, which catalyzes the reduced triphosphopyri- dine nucleotide-dependent reduction of dihydrofolic acid to tetrahydrofolic acid, was found to be stimulated markedly by high concentrations of urea' or low concentra- tions of organic mercurials.2 The similarity of the effects of both the mercurials and urea suggested that the stimulation of reductase activity is the result of a change in configuration of the protein molecule. The subsequent isolation of an enzyme- mercurial complex2 demonstrated that a specific interaction had occurred between the mercurial and the protein, presumably via a sulfhydryl group, yielding a cata- lytically more favorable enzyme. Similar results have recently been reported for dihydrofolic reductase from ascites carcinoma cells.3 It was of particular interest that other reagents known to react with sulfhydryl groups such as iodoacetamide, iodoacetic acid, and N-ethylmaleimide neither in- hibited nor stimulated the activity of dihydrofolic reductase. However, during reinvestigation of these reagents, it was noted that iodoacetamide or iodoacetic acid occasionally produced a marked stimulation of enzyme activity. These observa- tions led to the discovery that iodine derived from the breakdown of the iodocom- pounds was the source of this activation. The present study illustrates that inorganic iodine activates chicken liver di- hydrofolic reductase, presumably via the formation of a stable sulfenyl iodide. Materials and Methods.-Dihydrofolic reductase was prepared from chicken liver by the procedure of Kaufman and Gardiner.4 The preparations used in this study were either from the hydroxylapatite or carboxymethyl-Sephadex chromatographic steps. Dihydrofolic acid was prepared by the dithionite method of Futterman5 as modified by Blakely.6 TPNH was purchased from the California Corporation for Biochemical Research. Jodoacetamide was obtained from Mann Research Labora- tories and recrystallized from water-ethanol. Hydroxylapatite was prepared by the method of Levin.7 Sephadex G-25 was prepared as previously described.4 Sub- limed analytical grade iodine was obtained from J. T. Baker Chemical Company. Stock solutions of iodine were prepared in 0.2 M KI and standardized by using the equation described by Cunningham and Nuenke:8 meq I ml-' = 7.77 X 10-5 X OD at 355 mAu. Dilutions of the iodine stock solution were made either in 0.2 M KI or deionized distilled water. Dihydrofolic reductase was assayed by the spectrophotometric method based on the decrease in absorbance at 340 mg which occurs when TPNH and dihydrofolate are converted to tetrahydrofolate and TPN, respectively.4 Results.-Activation of dihydrofolic reductase by treatment wtth iodine: Figure 1 illustrates the marked increase in catalytic activity observed when the enzyme is pretreated with limiting quantities of iodine. Stimulation of activity 6-10-fold have 695 Downloaded by guest on September 29, 2021 696 BIOCHEMISTRY: B. T. KAUFMAN PRoc. N. A. S. FIG. 1.-Effect of iodine on the activity of dihydrofolic reductase. 0.35 - The reaction mixture in a vol of 1 ml contained: 50 mM potassium phos- phate buffer, pH 7.5; 0.2 mM TPNH; 0.30 _ 0.05 mM dihydrofolate; and enzyme preparation (equivalent to 10 pg protein). The enzyme preparation 0I25 was preincubated at room temperature for 2 min in the presence of the E phosphate buffer plus suitable aliquots of 2 X 10- N solution of iodine (1/ °QG20- a1000 aqueous dilution of 0.02 N iodine in 0.2 M KI) to yield the indicated final concentrations of iodine in the 1-ml reaction mixture. The reaction t / was initiated by the rapid addition of dihydrofolate and TPNH and the initial rate determined from the 0104 / decrease in absorbance at 340 mu. The control consisted of the same reaction mixture minus dihydrofolate. Enzyme preincubated with iodine as described above (o); enzyme preincubated as above plus 0.2 M KI (0); concentrated enzyme pre- 0 4 a 12 16 20 incubated at 0° for 24 hr with 50 IODINE (#Eq/ril X 107) Pmoles iodoacetamide prior to pre- incubation with iodine as above (v). been consistently observed under these test conditions. Similar results have been obtained by treating the concentrated enzyme directly with iodine prior to dilution into the assay cuvette. However, maintaining the concentrations of KI in the assay system at a constant level of 0.2 M markedly diminishes the maximal effect of iodine despite the fact that 0.2 M KI itself is capable of causing a 30-40 per cent increase in reductase activity. Evidence that this effect is probably mediated via a sulfhydryl group in the enzyme io also shown in Figure 1, since pretreatment of the enzyme with iodoacetamide completely abolishes the stimulation due to iodine. The effects of the co-substrates on the interaction of iodine with the enzyme could not be examn ed due to the rapid destruction of these very small amounts of iodine by either TPNH or dihydrofolate. Thus, no effect is observed if the iodine is ex- posed to the complete reaction mixture prior to the addition of the enzyme. Preparation of iodine-activated enzyme: Definitive evidence that the stimulation of the reduction of dihydrofolic acid is due to an activation of the enzyme is illus- trated by preparation and partial purification of the activated enzyme. Approxi- mately 200 ml of crude enzyme (eluate from Sephadex G-75)4 was titrated directly with successive increments (0.05 ml) of 0.016 N iodine. After each addition of iodine, the activity of an aliquot of the enzyme preparation was determined in the standard assay mixture without additional iodine. At the point of maximal stimu- lation (about 7 X) the enzyme solution was adsorbed and eluted from a hydroxylapa- tite column as previously described.4 The active fractions were combined, precipi- tated with ammonium sulfate (65-80 per cent saturation), and immediately desalted by passage through a column of Sephadex G-25. Table 1 summarizes the prepara- tion-of the activated enzyme. The iodine-activated enzyme appears to be relatively stable as evidence by the maintenance of the stimulated rate throughout these manipulations involving adsorption, elution, dilution, and concentration, as well as Downloaded by guest on September 29, 2021 VOL. 56, 1966 BIOCHEMISTRY: B. 7'. KAUFMAN 697 TABLE 1 Auo/Min/Mg of Protein* Step No addition + Mercaptoethanolt 1. Untreated enzyme 2.6 2.6 2. Iodine-treated enzyme 19.0 2.4 3. Hydroxylapatite eluate 81.0 11.5 4. Ammonium sulfate fraction (65-85% saturated) 98 13.5 5. Sephadex G-25 eluate 96 13.0 * Assay as described in Fig. 1, omitting the iodine. t Assay after 4-min preincubation with 20 mM mercaptoethanol. freezing and thawing. At each stage of the above procedure, the enhanced activity is reduced to the expected original activity by a 4-min preincubation with mercapto- ethanol. These observations, and particularly the reversal of the activation and recovery of the original activity at each step in the purification, essentially elimi- nate any explanation in terms of a release of inhibition by removal of an inactivator combined with the enzyme protein or of removal of some inhibitory impurity in the reaction mixture. Catalytic properties of the iodine-activated enzyme: Figure 2 illustrates the rate of reduction of dihydrofolate catalyzed by the iodine-activated enzyme and the original enzyme as a function of pH. After iodine treatment, the typical double pH optimum curve of the native enzyme is altered to a curve exhibiting a single opti- mum at approximately pH 6.3. This change in pH-activity response is essentially identical with that observed during urea and mercurial activation of the enzyme, with one interesting exception. It can be seen from Figure 2 that phosphate is inhibitory. In the case of the iodine-activated enzyme, 0.3 M potassium phosphate causes about 90 per cent inhibition of activity, whereas this concentration of phos- 0.6 100 0.5 s 0~~~~~~ 3. 2 0 ~~~~~04~~~~~~~~~~~~ *-_08>NM o~~~2 4 6 8 lo 12 3~^o T ME (minutes) 3 I 4 6 7 8 9 pH ~~~~~~FIG.3s.-Deactivation of iodine-activated mer&aptoethanol.,enzyme by Partially pur- FIG2.0 Activityof dihydrofolic re- ified iodine-treated enzyme (Table 1) was ductase after iodine treatment (Table 1) preincubated at room temperature for the and original enzyme as a function of pH. times indicated in the presence of phosphate The reaction mixture was that described buffer and 10 mM mercaptoethanol and inl Fig. 1, except for the use of the ap- assayed as described in Fig. 1: preincuba- propriate buffer (acetate-A; phosphate-v; tion with mercaptoethanol reaction initiated tris-o) at the indicated pH values in with TPNH and dihydrofolate (-); pre- both the experimental and control cuvettes incubation with mercaptoethanol and di- and the omission of any additional hydrofolate, reaction initiated with TPNH iodine. Solid line: iodine-treated enzyme; (0); preincubated with mercaptoethanol dashed line: an equivalent amount of and TPNH, reaction initiated with dihydro- untreated enzyme protein. folate (A). Downloaded by guest on September 29, 2021 698 BIOCHEMISTRY: B. 7'. KAUFMAN PROC. N. A. S. phate has no effect on either the untreated enzyme or the enzyme activated by urea or organic mercurials. Effects of sulfhydryl compounds: As previously mentioned, the addition of mer- captoethanol to the enzyme pretreated with iodine or to the enzyme purified after iodine treatment completely abolished the activation. Similar results were ob- tained with cysteine, glutathione, and thiourea. Figure 3 illustrates the deactiva- tion of the iodine-treated enzyme by mercaptoethanol. At a concentration of mercaptoethanol of 10 mM, approximately 6 min are required for complete deactiva- tion to occur.
Load more

Recommended publications
  • Methionine Synthase Supports Tumor Tetrahydrofolate Pools
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.05.284521; this version posted September 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Methionine synthase supports tumor tetrahydrofolate pools Joshua Z. Wang1,2,#, Jonathan M. Ghergurovich1,3,#, Lifeng Yang1,2, and Joshua D. Rabinowitz1,2,* 1 Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, New Jersey, USA 2 Department of Chemistry, Princeton University, Princeton, New Jersey, USA 3 Department of Molecular Biology, Princeton University, Princeton, New Jersey, USA # These authors contributed equally to this work. *Corresponding author: Joshua Rabinowitz Department of Chemistry and the Lewis-Sigler Institute for Integrative Genomics, Princeton University, Washington Rd, Princeton, NJ 08544, USA Phone: (609) 258-8985; e-mail: [email protected] Conflict of Interest Disclosure: J.D.R. is a paid advisor and stockholder in Kadmon Pharmaceuticals, L.E.A.F. Pharmaceuticals, and Rafael Pharmaceuticals; a paid consultant of Pfizer; a founder, director, and stockholder of Farber Partners and Serien Therapeutics. JDR and JMG are inventors of patents in the area of folate metabolism held by Princeton University. 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.09.05.284521; this version posted September 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Mammalian cells require activated folates to generate nucleotides for growth and division. The most abundant circulating folate species is 5-methyl tetrahydrofolate (5-methyl- THF), which is used to synthesize methionine from homocysteine via the cobalamin-dependent enzyme methionine synthase (MTR).
    [Show full text]
  • L-Carnitine, Mecobalamin and Folic Acid Tablets) TRINERVE-LC
    For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only (L-Carnitine, Mecobalamin and Folic acid Tablets) TRINERVE-LC 1. Name of the medicinal product Trinerve-LC Tablets 2. Qualitative and quantitative composition Each film- coated tablets contains L-Carnitine…………………….500 mg Mecobalamin……………….1500 mcg Folic acid IP…………………..1.5mg 3. Pharmaceutical form Film- coated tablets 4. Clinical particulars 4.1 Therapeutic indications Vitamin and micronutrient supplementation in the management of chronic disease. 4.2 Posology and method of administration For oral administration only. One tablet daily or as directed by physician. 4.3 Contraindications Hypersensitivity to any constituent of the product. 4.4 Special warnings and precautions for use L-Carnitine The safety and efficacy of oral L-Carnitine has not been evaluated in patients with renal insufficiency. Chronic administration of high doses of oral L-Carnitine in patients with severely compromised renal function or in ESRD patients on dialysis may result in accumulation of the potentially toxic metabolites, trimethylamine (TMA) and trimethylamine-N-oxide (TMAO), since these metabolites are normally excreted in the urine. Mecobalamin Should be given with caution in patients suffering from folate deficiency. The following warnings and precautions suggested with parent form – vitamin B12 The treatment of vitamin B12 deficiency can unmask the symptoms of polycythemia vera. Megaloblastic anemia is sometimes corrected by treatment with vitamin B12. But this can have very serious side effects. Don’t attempt vitamin B12 therapy without close supervision by healthcare provider. Do not take vitamin B12 if Leber’s disease, a hereditary eye disease.
    [Show full text]
  • Structural Basis for the Inhibition of Human 5,10-Methenyltetrahydrofolate Synthetase by N10-Substituted Folate Analogues
    Published OnlineFirst September 8, 2009; DOI: 10.1158/0008-5472.CAN-09-1927 Experimental Therapeutics, Molecular Targets, and Chemical Biology Structural Basis for the Inhibition of Human 5,10-Methenyltetrahydrofolate Synthetase by N10-Substituted Folate Analogues Dong Wu,1 Yang Li,1 Gaojie Song,1 Chongyun Cheng,1 Rongguang Zhang,2 Andrzej Joachimiak,2 NeilShaw, 1 and Zhi-Jie Liu1 1National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China and 2Structural Biology Center, Argonne National Laboratory, Argonne, Illinois Abstract of the one-carbon metabolic network, dihydrofolate reductase, 5,10-Methenyltetrahydrofolate synthetase (MTHFS) regulates which catalyzes the conversion of dihydrofolate to tetrahydrofolate. the flow of carbon through the one-carbon metabolic network, Similarly, colorectal and pancreatic cancers are routinely treated by which supplies essential components for the growth and administration of the pyrimidine analogue 5-fluorouracil (5-FU), proliferation of cells. Inhibition of MTHFS in human MCF-7 which inhibits thymidylate synthase (TS; ref. 6). TS converts breast cancer cells has been shown to arrest the growth of deoxyuridylate to deoxythymidylate using a carbon donated by cells. Absence of the three-dimensional structure of human 5,10-methylenetetrahydrofolate (Fig. 1). This conversion is essential MTHFS (hMTHFS) has hampered the rational design and for DNA synthesis (7). To increase the clinical efficiency of the optimization of drug candidates. Here, we report the treatment, 5-formyltetrahydrofolate is often coadministered along structures of native hMTHFS, a binary complex of hMTHFS with 5-FU. The beneficial effect of administering 5-formyltetrahy- with ADP, hMTHFS bound with the N5-iminium phosphate drofolate during the therapy with 5-FU is a consequence of the reaction intermediate, and an enzyme-product complex of 5,10-methenyltetrahydrofolate synthetase (MTHFS)–catalyzed hMTHFS.
    [Show full text]
  • Considerations for Crop Biofortification
    fpls-09-00443 April 4, 2018 Time: 16:15 # 1 REVIEW published: 06 April 2018 doi: 10.3389/fpls.2018.00443 Toward Eradication of B-Vitamin Deficiencies: Considerations for Crop Biofortification Simon Strobbe and Dominique Van Der Straeten* Laboratory of Functional Plant Biology, Department of Biology, Ghent University, Ghent, Belgium ‘Hidden hunger’ involves insufficient intake of micronutrients and is estimated to affect over two billion people on a global scale. Malnutrition of vitamins and minerals is known to cause an alarming number of casualties, even in the developed world. Many staple crops, although serving as the main dietary component for large population groups, deliver inadequate amounts of micronutrients. Biofortification, the augmentation of natural micronutrient levels in crop products through breeding or genetic engineering, is a pivotal tool in the fight against micronutrient malnutrition (MNM). Although these approaches have shown to be successful in several species, a more extensive knowledge of plant metabolism and function of these micronutrients is required to refine and improve biofortification strategies. This review focuses on the relevant B-vitamins Edited by: (B1, B6, and B9). First, the role of these vitamins in plant physiology is elaborated, Alexander Arthur Theodore Johnson, as well their biosynthesis. Second, the rationale behind vitamin biofortification is University of Melbourne, Australia illustrated in view of pathophysiology and epidemiology of the deficiency. Furthermore, Reviewed by: advances in biofortification, via metabolic engineering or breeding, are presented. Finally, Francesco Di Gioia, University of Florida, United States considerations on B-vitamin multi-biofortified crops are raised, comprising the possible Aymeric Goyer, interplay of these vitamins in planta.
    [Show full text]
  • Recombinant Human Dihydrofolate Reductase/DHFR
    Recombinant Human Dihydrofolate Reductase/DHFR Catalog Number: 8456-DR DESCRIPTION Source E. coli­derived Met1­Asp187, with a C­terminal 6­His tag Accession # P00374 N­terminal Sequence Met1 & Val2 Analysis Predicted Molecular 22 kDa Mass SPECIFICATIONS SDS­PAGE 23 kDa, reducing conditions Activity Measured by the reduction of dihydrofolic acid (DHF). The specific activity is >5,500 pmol/min/μg, as measured under the described conditions. Endotoxin Level <1.0 EU per 1 μg of the protein by the LAL method. Purity >95%, by SDS­PAGE under reducing conditions and visualized by Colloidal Coomassie® Blue stain at 5 μg per lane. Formulation Supplied as a 0.2 μm filtered solution in Tris, NaCl, Glycerol, Brij­35 and DTT. See Certificate of Analysis for details. Activity Assay Protocol Materials l Assay Buffer: 50 mM MES, 25 mM Tris, 100 mM NaCl, 25 mM Ethanolamine, 2 mM DTT l Recombinant Dihydrofolate Reductase/DHFR (rhDHFR) (Catalog # 8456­DR) l β­Nicotinamide adenine dinucleotide phosphate reduced, tetrasodium salt (β­NADPH) (Sigma, Catalog # N7505), 10 mM stock in deionized water l Dihydrofolic acid (DHF) (Sigma, Catalog # D7006), 10 mM stock in Assay Buffer + 4.5 mM NaOH l 96­well Clear Plate (Catalog # DY990) l Plate Reader (Model: SpectraMax Plus by Molecular Devices) or equivalent Assay 1. Dilute rhDHFR to 1 μg/mL in Assay Buffer. 2. Prepare a Substrate Mixture containing 0.2 mM DHF and 0.25 mM β­NADPH in Assay Buffer. 3. Load 50 μL of 1 μg/mL rhDHFR into a plate, and start the reaction by adding 50 μL of Substrate Mixture.
    [Show full text]
  • Oral Immunosuppressive Drugs in the Treatment of Atopic Dermatitis
    Oral immunosuppressive drugs in the treatment of atopic dermatitis IMPROVING PERFORMANCE AND SAFETY FLOOR M. GARRITSEN Colofon Oral immunosuppressive drugs in the treatment of atopic dermatitis Improving performance and safety Thesis with a summary in Dutch, Utrecht University, the Netherlands © Floor Garritsen, 2018 No part of this thesis may be reproduced, stored or transmitted, in any form or by any means, without prior permission of the author. ISBN: 978-90-393-6931-9 Cover design and layout: Die Jongens Printed and published by: Proefschriftmaken.nl Oral immunosuppressive drugs in the treatment of atopic dermatitis: improving performance and safety Orale immunosuppressiva bij de behandeling van constitutioneel eczeem: het verbeteren van effectiviteit en veiligheid (met een samenvatting in het Nederlands) Proefschrift ter verkrijging van de graad van doctor aan de Universiteit Utrecht op gezag van de rector magnificus, prof. dr. G.J. van der Zwaan, ingevolge het besluit van het college voor promoties in het openbaar te verdedigen op donderdag 8 februari 2018 des middags te 2.30 uur door Floralie Maria Garritsen geboren op 22 oktober 1986 te Beek en Donk Promotor: Prof. dr. C.A.F.M. Bruijnzeel-Koomen Copromotoren: Dr. M.S. de Bruin-Weller Dr. M.P.H. van den Broek Table of contents Chapter 1 General introduction 7 Part I – Qualitative and quantitative exploration of oral immunosuppressive drug use in the Netherlands Chapter 2 Ten years experience with oral immunosuppressive treatment 23 in adult patients with atopic dermatitis in two
    [Show full text]
  • BIOPAR DELTA-FORTE- 1 Nf Units, 50 Mcg Cbl, 2.5 Mg F-Thf, 1
    BIOPAR DELTA-FORTE- 1 nf units, 50 mcg cbl, 2.5 mg f-thf, 1 mg pteglu-, 7 mg me- thf capsule Jaymac Pharmacueticals LLC Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here. ---------- BioparTM delta-FORTE DESCRIPTION [1 NF Units] [50 mcg CBl] [2.5 mg F-THf] [1 mg PteGlu-] [7 mg Me-THf] Prescription Hematopoietic Preparation For Therapeutic Use Multiphasic Softgels (30ct carton) NDC 64661-793-30 Rx ONLY BioparTMdelta-FORTE is an orally administered prescription hematopoietic preparation for therapeutic use formulated for adult macrocytic anemia patients – specifically including pernicious anemia patients, ages 12 and up, who are under specific direction and monitoring of cobalamin and folate status by a physician. A recent study+ suggested that BioparTM delta-FORTE was effective in lowering homocysteine levels in patients that are positive for MTHFR (methylenetetrahydrofolate reductase polymorphism). BioparTM delta-FORTE may be taken by women of childbearing age. BioparTM delta- FORTE may be taken by geriatric patients where compliance is an issue. + ClinicalTrials.gov identifier: NCT02709668, Correlation of Clinical Response With Homocysteine Reduction During Therapy With Reduced B Vitamins in Patients with MDD Who Are Positive for MTHFR C677T or A1298C Polymorphism. INGREDIENTS Cobalamin-intrinsic factor concentrate (non-inhibitory)1 .............................................................................................
    [Show full text]
  • GRAS Notice 915, Calcium L-Methylfolate
    GRAS Notice (GRN) No. 915 https://www.fda.gov/food/generally-recognized-safe-gras/gras-notice-inventory Form Approved: 0MB No. 0910-0342; Expiration Date: 09/30/2019 (See last naae for 0MB Statement) FDA USE ONLY , 'GRN NUM~ER QATE OF. RECEIF!T DEPARTMENT OF HEALTH AND HUMAN SERVICES -- - ESTIMATED DAlllY·INTAKE fNTENDED USE FQ~ INTERNET Food and Drug Administration Ii .. GENERALLY RECOGNIZED AS SAFE -- 'NAME F:OR INTERNET (GRAS) NOTICE (Subpart E of Part 170) - - ,~ Y.WORDS I l I ~ .. Transmit completed form and attachments electronically via the Electronic Submission Gateway (see Instructions); OR Transmit completed form and attachments in paper format or on physical media to: Office of Food Additive Safety (HFS-200), Center for Food Safety and Applied Nutrition, Food and Drug Administration,5001 Campus Drive, College Park, MD 20740-3835. SECTION A- INTRODUCTORY INFORMATION ABOUT THE SUBMISSION 1. Type of Submission (Check one) ~ New D Amendment to GRN No. D Supplement to GRN No. 2. [gl All electronic files included in this submission have been checked and found to be virus free. (Check box to verify) 3 Mosl recent presuom1ss1on meeung (" any) w1m FDA on the subject substance (yyyylmmldd): 12/17/2018 4 For Amendments or Supplements: Is your (Check one) amendment or supplement submitted in D Yes If yes, enter the date of response lo a communication from FDA? D No communication (yyyy/mmldd): ______ SECTION B - INFORMATION ABOUT THE NOTIFIER Name of Contact Person Position or Title William Turney Head of Regulatory Affairs NA Organization (if applicable) 1 a. Notifier DSM Nutritional Products Mailing Address (number and street) 45 Waterview Blvd.
    [Show full text]
  • The Changing Faces of Vitamin B12 and Folic Acid – Part Two: Integration of Symptoms, and Genetic Testing to Select the Best Drugs for Your Patient
    The Changing Faces of Vitamin B12 and Folic Acid – Part two: Integration of symptoms, and genetic testing to select the best drugs for your patient By: Dan Carter, ND The symptoms of vitamin B12 deficiency range from mild to severe, and in many cases are not specific enough to confirm a diagnosis. Symptoms can include diarrhea or constipation, fatigue, light headedness on standing, poor appetite, pallor, difficulty concentrating, shortness of breath on exertion, glossitis. Neurologic symptoms can appear after chronic deficiency and involve changes in mental status, depression, peripheral neuropathy, loss of balance. [Anemia – B12 deficiency. http://www.nlm.nih.gov/medlineplus/ency/article/000574.htm] Some of the symptoms of folate deficiency overlap with B12, including fatigue and glossitis, but others such as accelerated graying of hair, oral ulcers, and poor growth rates do not. [Folate deficiency. http://www.nlm.nih.gov/medlineplus/ency/article/000354.htm] The indicated blood tests for B12 deficiency are complete blood count (CBC), reticulocyte count, serum LDH and vitamin B12, while those for folate deficiency are CBC, serum and RBC folate. Other useful tests are serum homocysteine and methylmalonic acid (MMA). Serum homocysteine will be high with both deficiencies, while only MMA will be increased in B12 deficiency. [Vitamin B12 and Folate. http://labtestsonline.org/understanding/analytes/vitamin-b12/tab/test] As genetic testing has become more widely available, specific analysis of known single nucleotide polymorphisms (SNP) is increasingly accepted as an aid to diagnosis. In the case of folate metabolism several SNP have been identified as significant; the first SNP to gain widespread attention affected the MTHFR gene.
    [Show full text]
  • Simulation of Food Folate Digestion and Bioavailability of an Oxidation Product of 5-Methyltetrahydrofolate
    Article Simulation of Food Folate Digestion and Bioavailability of an Oxidation Product of 5-Methyltetrahydrofolate Christiane Ringling 1 and Michael Rychlik 1,2,* 1 Division BIOANALYTIK Weihenstephan, Research Center for Nutrition and Food Sciences (Z. I. E. L.), Technical University of Munich, Alte Akademie 10, D-85350 Freising, Germany; [email protected] 2 Chair of Analytical Food Chemistry, Technical University of Munich, Alte Akademie 10, D-85350 Freising, Germany * Correspondence: [email protected]; Tel.: +49-8161-71-3746; Fax: +49-8161-71-4216 Received: 22 July 2017; Accepted: 28 August 2017; Published: 1 September 2017 Abstract: Generating bioavailability data from in vivo studies is time-consuming and expensive. In vitro simulation can help to investigate factors influencing bioavailability or facilitate quantifying the impact of such factors. For folates, an efficient deconjugation of polyglutamates to the corresponding monoglutamates is crucial for bioavailability and highly dependent on the food matrix. Therefore, the bioaccessibility of folates of different foodstuffs was examined using a simulated digestion model with respect to folate stability and the efficiency of deconjugation. For realistic simulated deconjugation, porcine brush border membrane was used during the phase of the simulated digestion in the small intestine. For a better understanding of folate behaviour during digestion, single folate monoglutamates were also investigated with this in vitro digestion model. The results for bioaccessibility were compared with data from a human bioavailability study. They support the idea that both stability and deconjugation have an influence on bioaccessibility and thus on bioavailability. Tetrahydrofolate is probably lost completely or at least to a high extent and the stability of 5-methyltetrahydrofolate depends on the food matrix.
    [Show full text]
  • Produktinformation Todavit
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT TODAVİT powder for solution for I.M./I.V. injection/ infusion Sterile 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active Substance: In each vial; Vitamin A (as Retinol palmitate) 3500 IU (2,06 mg) Vitamin D3 (Cholecalciferol) (made from sheep wool.) 220 IU (0,22 mg) Vitamin E (11,2 mg Vitamin E as acetate) 11,2 IU Vitamin C (Ascorbic acid ) 125 mg Vitamin B1 (Thiamine; 3,935 mg asThiamine HCl) 3,51 mg Vitamin B2 (Riboflavin; 5,26 mg Riboflavin sodium phosphate) 4,14 mg Vitamin B6 (Piridoxin; 5,5 mg as Piridoxin hydrochloride) 4,53 mg Vitamin B12 (Cyanocobalamin) 0,006 mg Folik acid 0,414 mg Pantothenic acid (16,15 mg asDexpanthenol) 17,25 mg D-Biotin 0,069 mg Nicotinamide 46 mg Excipients: Sodium hydroxide: q.s. Soy lecithin: 112.5 mg For a full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Yellow-orange colored lyophilized cake. Sterile. 4. CLINICAL PARTICULARS 4.1. Therapeutic indications In accordance with the daily needs of adults and children over 11 years of age,it is indicated when oral intake is contraindicated or inadequate (malnutrition, gastrointestinal malabsorption, parenteral nutrition, etc.) or when it is not possible, intravenously. 1/15 4.2. Posology and method of administration Posology / Application frequency and duration: In adults and children over 11 years old, the daily dose is 1 vial. In special cases with increased nutritional requirements (severe burns, etc.), high doses such as 2-3 vials daily can be used. Method of Application: It is used intravenously or intramuscularly.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0035087 A1 Barclay (43) Pub
    US 20020035087A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0035087 A1 Barclay (43) Pub. Date: Mar. 21, 2002 (54) B COMPLEX VITAMIN COMPOSITIONS (57) ABSTRACT THAT PROTECT AGAINST CELLULAR The present invention relates generally to the use of Vitamin DAMAGE CAUSED BY ULTRAVIOLET B12 (cobalamin or cyanocobalamin) alone or in combina LIGHT tion with other photoprotective agents, including Specifically other vitamins such as vitamin B9 (folic acid or folate) and Vitamin B3 (niacin or niacinamide), or any chemical deriva (76) Inventor: Barry J. Barclay, St. Albert (CA) tive of these Vitamins and their Salts, as a filter to protect cells against the damaging effects of ultraviolet (UV) light. The invention is, in one aspect, a method of reducing the rate Correspondence Address: of UV damage to cells exposed to a UV light source, by Kevin S. Lemack treating the celis with the Vitamin composition, either alone Nields & Lemack or in combination with other photoprotective agents. Other 176 E. Main Street - Suite 8 aspects of the invention are compositions comprising effec Westboro, MA 01581 (US) tive amounts of vitamin B12 alone or in combination with other photoprotective agents including Vitamin B9 and Vita min B3 and a pharmaceutically-acceptable carrier, that are (21) Appl. No.: 09/900,064 useful in protecting cells, particularly Skin cells, against the burning, genotoxic (mutagenic and carcinogenic), immuno (22) Filed: Jul. 6, 2001 Suppressive and photoaging effects of UV light, especially Sunlight. The invention has application as a UV light filter in (30) Foreign Application Priority Data oral preparations including tablets and drinks, topical creams, lotions, sprays, wipes and cosmetics.
    [Show full text]